Clinical System for Arterial Tissue Characterization

动脉组织表征的临床系统

• 批准号: 6736538
• 负责人: STEPHEN FREDERICK FULGHUM
• 金额: $ 9.98万
• 依托单位: NEWTON LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-02-01 至 2005-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6736538
• 关键词: atherosclerotic plaque; biomedical equipment development; cardiovascular disorder diagnosis; diagnosis design /evaluation; fluorescence spectrometry; fluorescent dye /probe; optics

DESCRIPTION (provided by applicant): Atherosclerosis is the leading cause of death in industrialized countries, worldwide. In the United States, myocardial infarctions, almost entirely attributable to coronary artery atherosclerosis, account for 20 to 25% of all deaths. Therapies are available, but no reliable methods can predict in advance which lesions will progress. One major reason is that in situ biopsies of blood vessels is difficult and risky, so histopathology cannot be used routinely to provide information about the state of diseased vessels. A substantial literature of in vitro studies show that fluorescence spectroscopy of arterial walls can distinguish between normal, atherosclerotic and calcified atherosclerotic plaque. Few successful in vivo studies have been done, however, for several reasons. One reason is the lack of a suitable optical probe. Another reason is that hemoglobin absorption often distorts the fluorescence signatures to the point where they cannot be properly analyzed. NLI proposes to address these limitations by designing, fabricating and testing a new side-looking optical probe which will measure, in vivo, both fluorescence and reflectance from arterial tissue. From these two measurements intrinsic fluorescence spectra, undistorted by scattering and absorption processes can be obtained, which will greatly improve the reliability of the optical diagnosis.

描述（由申请人提供）：动脉粥样硬化是全世界工业化国家的首要死因。在美国，几乎完全由冠状动脉粥样硬化引起的心肌梗塞占所有死亡人数的 20% 至 25%。治疗方法是可用的，但没有可靠的方法可以提前预测哪些病变将进展。一个主要原因是血管原位活检既困难又危险，因此不能常规使用组织病理学来提供有关病变血管状态的信息。大量体外研究文献表明，动脉壁荧光光谱可以区分正常、动脉粥样硬化和钙化动脉粥样硬化斑块。然而，由于多种原因，很少有成功的体内研究。原因之一是缺乏合适的光学探头。另一个原因是血红蛋白吸收常常会扭曲荧光特征，以致无法正确分析。 NLI 建议通过设计、制造和测试一种新的侧视光学探针来解决这些限制，该探针将在体内测量动脉组织的荧光和反射率。从这两次测量中可以获得不因散射和吸收过程而失真的本征荧光光谱，这将大大提高光学诊断的可靠性。